Phase 2 N=28 Effects of rhIGF-1 on Bone Metabolism in Adolescent Girls With Anorexia Nervosa
Disorder of Bone Density and Structure, Unspecified
Primary: Change in Spine Bone Density (g/cm^2) — -0.00558 gm/cm^2 — p=0.40
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=45 Study of Vitamin D and Effect on Heart Disease and Insulin Resistance
Human Immunodeficiency Virus (HIV) · Vitamin D Deficiency · HIV Infections
Primary: Change in Endothelial Function — 0.29; 0.55 percent change in endothelial function
Phase 2 N=643 An Efficacy Study of Compound LY2624803 in the Treatment of Patients With Chronic Insomnia
Primary Insomnia · Secondary Insomnia
Primary: Change From Baseline in Average Nightly Total Sleep Time at Week 4 (Week 2 of Period B) Endpoint — 30.16; 37.33; 50.63; 22.79 minutes
Phase 2 N=31 Safety Evaluation of Dasatinib in Subjects With Scleroderma Pulmonary Fibrosis
Scleroderma
Primary: Number of Participants Who Died, Experienced Serious Adverse Events (SAEs), or Adverse Events (AEs) — 0; 31; 7; 0 Participants
Phase 2 N=78 Thalidomide and Temozolomide or Camptothecin-11 (CPT-11) in Patients With Gliomas
Glioblastoma Multiforme · Glioma
Primary: Number of Participants Progression Free at 6 Months With Malignant Gliomas — 24 participants
Phase 2 N=98 A Study to Demonstrate the Analgesic Efficacy of Oxycodone/Naloxone Prolonged Release Tablets in Addition to Pregabalin Compared to Pregabalin Alone in Opioid-naïve Subjects Treated With Pregabalin Suffering From Moderate to Severe Pain Due to Diabetic Polyneuropathy
Moderate to Severe Pain Due to Diabetic Polyneuropathy
Primary: Short Form McGill Pain Score. — 49.56; 47.65 units on a scale
Phase 2 N=80 Phase I/II Trial of Fludarabine Plus Busulfan and Allogeneic Progenitor Cell Support
Hematologic Malignancies
Primary: Maximum Tolerated Dose (MTD) — 11.2 mg/kg
Phase 2 N=15 Open-Label Disulfiram for Methamphetamine Dependence
Methamphetamine Dependence
Primary: Side Effects Checklist — 9.6515 units on a scale — p=0.05
Phase 2 N=30 An Open-Label Functionality, Safety and Efficacy Study in Patients Undergoing Elective Unilateral Knee Replacement
Pain, Postoperative
Primary: Percent of Patients Without Device Failure — 100 percent
Phase 2 N=20 Trial of Topical Cidofovir for the Prevention of Hair Growth
Prevention of Hair Growth
Primary: Physician's Global Assessment (PGA) of Hair Density — 1; 0; 1 participants
Phase 2 N=151 Use of Silodosin to Treat Moderate to Severe Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome.
Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome
Primary: National Institutes of Health-Chronic Prostatitis Symptom Index (NIH-CPSI) Total Score. — 26.0; 26.8; 27.9; -12.1 Units on a 0 to 43 scale
Phase 2 N=77 Efficacy and Safety Study of D9421-C 9 mg and 15 mg Versus Placebo in Japanese Patients With Active Crohn's Disease
Crohn's Disease
Primary: Number of Participants Who Had Remission of Crohn's Disease After 8-week Treatment — 6; 7; 3 Participants
Phase 2 N=29 Eloxatin® Plus Gemcitabine Chemotherapy for Mesothelioma
Mesothelioma
Primary: Best Response — 0; 7; 11; 11 participants
Phase 2 N=32 Sequential Vaccinations in Prostate Cancer Patients
Prostatic Neoplasms
Primary: Number of Participants With an Immune Response — 2; 4; 4; 3 Participants
Phase 2 N=48 Study of Gamma Interfereon in Metastatic Colorectal Carcinoma
Colorectal Cancer
Primary: Best Response (BR) — 0; 0; 6; 3 Participants